Novo Nordisk's Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
Fox Business13d
Novo Nordisk shares fall on weight-loss drug trial
Shares of Novo Nordisk slipped ... were given the highest dose of the drug, which combines the GLP-1 agonist semaglutide, the active ingredient in Wegovy and Ozempic, and a cagrilintide, a ...
Seeking Alpha12d
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk ... dose after 68 weeks of treatment. If we compare across trials, CagriSema looks comparable to tirzepatide in efficacy and significantly better than semaglutide (Ozempic/Wegovy).
Morningstar13d
Here's why Ozempic maker's new weight-loss drug isn't good enough for investors
New trial data showed CagriSema led to 'superior' weight loss, but at a rate less than expectations Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy ...
Weight loss drug Mounjaro launched in India: Know price, how it works, side-effects, and if it’s more effective than Ozempic
The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...
Weight Loss Drug Mounjaro Launched In India To Tackle Obesity: Is It More Effective Than Ozempic?
Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...